Betta Pharmaceuticals Co., Ltd. Class A 300558

Xcovery Holdings, Inc., (Xcovery) an evidence-based, innovation-driven pharmaceutical company, today announced an agreement with EVERSANA®, a leading provider of commercialization services to the global life sciences industry, to support and expand the U.S. commercial launch of ENSACOVE™ (ensartinib), the company's novel therapy for adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).

Eleven Chinese healthcare and biotechnology companies filed applications to list on the Hong Kong stock exchange in the last two days of September, taking advantage of an ongoing investment boom in the sector. The best-known names among them are online healthcare services firm We Doctor Holdings, Sichuan Biokin Pharmaceutical - known for a US$8.4 billion licensing deal with US-based Bristol Myers Squibb (BMS) - and profitable cancer-drug developer Betta Pharmaceuticals. Other initial public offe